Set Targets Not Price Limits, German Industry Pleads

Plans for reference-price group for four anti-TNFs, including adalimumab and etanercept

 
• By Aidan Fry

Grouping together biosimilar adalimumabs and etanercepts with patented biologics in the same reference-price group in Germany threatens to remove biosimilars’ market advantage and weaken competition, local industry fears.

Antibody
Therapeutic comparability between four TNF-alpha inhibitors has led German authorities to propose putting them in the same reference-pricing group • Source: Shutterstock

More from Biosimilars

More from Products